Study on the Effects of Teduglutide on the Gut Microbiota of Pediatric Patients with Short Bowel Syndrome

Study on the Impact of GLP-2 Analogue Therapy on the Gut Microbiota in Children with Short Bowel Syndrome - GLP-2 Analogues and Gut Microbiota in Pediatric Short Bowel Syndrome

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058962

Enrollment

Registered

2025-09-10

Start date

2025-08-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Short Bowel Syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children with short bowel syndrome (SBS) aged 15 years or younger receiving teduglutide

Exclusion criteria

Exclusion criteria: Patients who have had an infectious or inflammatory disease within the past 3 months Patients who have been receiving teduglutide for less than 1 month since initiation Patients deemed ineligible by the principal investigator for any other reason

Design outcomes

Primary

Measure	Time frame
Characteristics of gut microbiota diversity indices in pediatric SBS patients receiving teduglutide Dominant bacterial taxa in the gut microbiota of pediatric SBS patients receiving teduglutide	—

Secondary

Measure	Time frame
Correlation between gut microbiota and clinical parameters in pediatric SBS patients receiving teduglutide Functional prediction of the gut microbiota in pediatric SBS patients receiving teduglutide	—

Countries

Japan

Contacts

Public ContactTsubasa Aiyoshi

University of Tsukuba Hospital Department of Pediatric Surgery

t.aiyoshi@md.tsukuba.ac.jp0298533516

Outcome results